Mycophenolate Sodium
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MYFORTIC | — | 2004-02-27 | fda.gov ↗ |
Trials 64 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00542763 | Apr 2005 → Sep 2007 | Sjogren syndrome | University Hospital Muenster | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00856505 | Mar 2008 → Mar 2010 | hematologic disorder | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT00890253 | Jan 2010 → Jan 2012 | chronic renal failure syndrome | Armin Goralczyk | Unknown | No outcome recorded |
| Phase 2 | NCT00423098 | Feb 2007 → Nov 2009 | lupus nephritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 323 trials · 1 missed | ||||||
| Phase 3 | NCT02334488 | Dec 2014 → May 2019 | chronic kidney disease | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01410448 | Nov 2011 → Dec 2015 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT01015456 | Jan 2010 → Jan 2013 | lupus nephritis | Chulalongkorn University | Terminated | No outcome recorded |
| Phase 3 | NCT00966836 | Apr 2009 → Apr 2012 | cytomegalovirus infection | University of Bologna | Unknown | No outcome recorded |
| Phase 3 | NCT00405652 | Jan 2007 → Sep 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00369278 | Jun 2006 → Dec 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00351377 | Jun 2006 → Jun 2009 | autoimmune disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00267150 | Nov 2005 → Jan 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00149903 | Jan 2005 → Jun 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00284921 | Apr 2004 → Aug 2006 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00171379 | Mar 2004 → Jun 2005 | acute transplant rejection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171392 | Mar 2004 → Jun 2005 | acute transplant rejection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00262132 | Sep 2003 → Aug 2006 | pulmonary sarcoidosis | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 3 | NCT00239070 | Apr 2003 → May 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00238446 | Apr 2003 → Jun 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00238940 | Feb 2003 → Sep 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00239044 | Dec 2002 → Jul 2005 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00238992 | Dec 2002 → Jul 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00239057 | May 2002 → Jan 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00239031 | Mar 2002 → Jul 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00149916 | Apr 2000 → Apr 2004 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00149864 | Feb 2000 → Dec 2003 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00149929 | Dec 1999 → Apr 2003 | — | Novartis | Completed | No outcome recorded |
| Phase 436 trials · 1 missed | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05872568 | Jun 2023 → Dec 2025 | transplant rejection | Zhishui Chen | Unknown | No outcome recorded |
| Phase 4 | NCT04177095 | Feb 2020 → Sep 2021 | transplant rejection | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02453867 | Dec 2017 → Jul 2018 | disease related to solid organ transplantation | Klemens Budde | Unknown | No outcome recorded |
| Phase 4 | NCT01822483 | Apr 2013 → Mar 2015 | — | Irmandade Santa Casa de Misericórdia de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT01801280 | Jan 2012 → Mar 2013 | disease related to solid organ transplantation | Klemens Budde | Completed | No outcome recorded |
| Phase 4 | NCT01817322 | Jun 2011 → Aug 2013 | chronic kidney disease | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01056822 | May 2010 → Apr 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01159080 | Apr 2010 → Oct 2016 | — | Asan Medical Center | Completed | Mixed |
| Phase 4 | NCT00652834 | Apr 2009 → Mar 2011 | gastrointestinal polyp | University of California, Los Angeles | Completed | Missed primary |
| Phase 4 | NCT00646737 | May → Dec 2008 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00434590 | Mar 2007 → May 2008 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00529269 | Dec 2006 → Jun 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00419926 | Dec 2006 → Jun 2009 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00400400 | Oct 2006 → Jun 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00676221 | Jul 2006 → Aug 2008 | — | Foothills Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT00400647 | Jul 2006 → Sep 2008 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00574197 | Jun 2006 → Dec 2009 | — | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00537862 | May 2006 → Feb 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00371826 | Mar 2006 → Jun 2012 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00239005 | Sep 2005 → Mar 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00149968 | Apr 2005 → Jan 2007 | digestive system disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00238953 | Feb 2005 → Jun 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00239083 | Jan 2005 → Aug 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00149942 | Oct 2004 → Aug 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00150020 | Oct 2004 → Feb 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00154206 | Sep 2004 → Jan 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00154232 | Jun 2004 → Mar 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00150007 | Jun 2004 → Jun 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00240955 | Mar 2004 → May 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00312143 | Feb 2004 → Oct 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00154245 | Jan 2004 → Mar 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00239018 | Apr 2003 → Jul 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00238979 | Jan 2003 → Feb 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00238966 | Nov 2002 → Apr 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00241059 | Aug 2002 → Jan 2005 | — | Novartis | Completed | No outcome recorded |
| Comparator or background therapy44 trials | ||||||
| Phase 0 | NCT06663046 Background | Jul 2025 → Dec 2027 | plasma cell myeloma, refractory plasma cell neoplasm | Wondercel Biotech (ShenZhen) | Suspended | No outcome recorded |
| Phase 0 | NCT06662227 Background | Oct 2024 → Dec 2027 | B-cell neoplasm, lymphoid leukemia | Wondercel Biotech (ShenZhen) | Suspended | No outcome recorded |
| Phase 0 | NCT06653023 Background | Oct 2024 → Oct 2027 | hepatocellular carcinoma, non-small cell lung carcinoma | Wondercel Biotech (ShenZhen) | Suspended | No outcome recorded |
| Phase 1 | NCT04375631 Background | Dec 2020 → Feb 2027 expected | acute undifferentiated leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT02167958 Background | Feb 2015 → Sep 2019 | leukemia, lymphoma, myelodysplastic syndrome, myelofibrosis | Rafic Farah, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00810602 Background | Jan 2009 → Apr 2013 | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Pavan Reddy, MD | Completed | No outcome recorded |
| Phase 2 | NCT06646497 Background | Jan 2025 → Jan 2030 expected | acquired aplastic anemia | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT05156710 Background | Jun 2022 → Oct 2025 overdue | transplant rejection | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05263505 Comparator | Feb 2022 → Sep 2023 | conjunctivitis, mucous membrane pemphigoid | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT04195633 Background | Jan 2021 → Apr 2027 expected | Burkitt lymphoma, Hodgkins lymphoma, anaplastic large cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma +10 | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03917797 Background | Apr 2019 → Dec 2024 | lupus nephritis, systemic lupus erythematosus | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase 2 | NCT03644667 Background | Dec 2018 → Mar 2025 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03434704 Background | Jun 2018 → Oct 2019 | acute leukemia, fungal infectious disease, graft versus host disease, myelodysplastic syndrome | Ciceri Fabio | Completed | No outcome recorded |
| Phase 2 | NCT02885610 Comparator | Dec 2015 → Jun 2019 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT01790594 Background | Feb 2013 → Aug 2016 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT01490723 Background | Jan 2013 → Apr 2019 | leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01320358 Background | May → Nov 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00639717 Background | Mar 2009 → Jan 2012 | graft versus host disease | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00775632 Comparator | Oct 2008 → Sep 2010 | graft versus host disease | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01053221 Comparator | Mar 2006 → Aug 2012 | — | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT07412470 Background | Mar 2026 → Aug 2029 expected | transplant rejection | Sanofi | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00533624 Comparator | Dec 2004 → Feb 2006 | end stage renal failure | University of Miami | Completed | No outcome recorded |
| Phase 3 | NCT04945096 Background | Jul 2021 → Jul 2025 | graft versus host disease | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT01680861 Comparator | Nov 2012 → Dec 2014 | — | Gaetano Ciancio | Completed | Missed primary |
| Phase 3 | NCT01639339 Background | Jul 2012 → Jul 2019 | lupus nephritis | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00425308 Comparator | Oct 2006 → May 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00308425 Background | Oct 2002 → Jun 2005 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT04936282 Comparator | Jul 2022 → Jun 2027 expected | chronic transplant rejection | Canary Isles Institute for Health Research Foundation | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04424602 Comparator | Apr → Sep 2021 | lupus nephritis | Al-Azhar University | Completed | No outcome recorded |
| Phase 4 | NCT02953873 Background | May 2017 → Sep 2018 | immunodeficiency disease | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT02671318 Comparator | Sep 2015 → Dec 2019 | cytomegalovirus infection | Hospital do Rim e Hipertensão | Unknown | No outcome recorded |
| Phase 4 | NCT06584773 Comparator | Jun 2015 → Aug 2024 overdue | disease related to solid organ transplantation | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02152345 Background | Jun 2014 → Dec 2016 | transplant rejection | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT02683291 Comparator | Jan 2014 → Jan 2015 | cytomegalovirus infection, disease related to solid organ transplantation | Associação Médico Espírita de Botucatu | Completed | No outcome recorded |
| Phase 4 | NCT01927588 Comparator | Aug 2013 → Nov 2015 | cytomegalovirus infection | Fundação Pró Rim | Unknown | No outcome recorded |
| Phase 4 | NCT01895049 Comparator | Aug 2013 → Mar 2016 | cytomegalovirus infection | Helio Tedesco Silva Junior | Completed | Met primary |
| Phase 4 | NCT02084446 Comparator | Dec 2012 → Jul 2014 | cytomegalovirus infection, disease related to solid organ transplantation | Ronaldo de Matos Esmeraldo, MD | Completed | No outcome recorded |
| Phase 4 | NCT01729494 Background | Sep 2012 → Dec 2018 | — | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT01354301 Comparator | May 2011 → Apr 2014 | cytomegalovirus infection, transplant rejection | Hospital do Rim e Hipertensão | Completed | Met primary |
| Phase 4 | NCT00965094 Background | Dec 2009 → Jun 2013 | chronic renal failure syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01112215 Comparator | Dec 2009 → Dec 2015 | systemic lupus erythematosus | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00866684 Comparator | Jan 2007 → Apr 2011 | skin cancer | Charite University, Berlin, Germany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00574743 Comparator | Jan 2002 → Apr 2004 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| — | NCT01807767 Background | Mar 2013 → Jul 2015 | — | Medical College of Wisconsin | Withdrawn | No outcome recorded Stop: Business |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-21 | Zydus Lifesciences Limited | Zydus receives Prior Approval Supplement (PAS) approval from USFDA for Mycophenolate Mofetil for Injection USP zyduslife.com ↗ |
| 2019-10-14 | Hoffmann-La Roche | Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris roche.com ↗ |
| 2017-08-24 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Mycophenolate Mofetil for Injection USP zyduslife.com ↗ |
| 2009-05-05 | Zydus Lifesciences Limited | Zydus receives approval for Mycophenolate Mofetil tablets and capsules zyduslife.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 116 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mycophenolate sodium | “One day after the completion of fludarabine preconditioning (D-2), initiate oral mycophenolate sodium at a dose of 1440 mg twice daily (BID) for 15 consecutive days, or extend...” NCT06653023 ↗76“Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study” NCT01159080 ↗ “A Prospective, Open-label, Multicenter Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Heart Transplant Recipients” NCT00238446 ↗ “Myfortic® is an advanced, enteric coated formulation of mycophenolate sodium (EC-MPS) that delays the release of the active ingredient, MPA.” NCT00652834 ↗ “de-novo CNI-free immunosuppression with basiliximab, mycophenolate sodium, prednisolone and everolimus” PMID 20380712 ↗ Apr 2010 “initiate oral mycophenolate sodium at a dose of 1440 mg twice daily (BID) for 15 consecutive days” NCT06662227 ↗ “Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months” NCT01053221 ↗ “Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day).” NCT01729494 ↗ “Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.” NCT00676221 ↗ “Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.” NCT03644667 ↗ “In this study, the IEM was combined to enteric-coated mycophenolate sodium (ECMPS).” PMID 23823651 ↗ Aug 2013 |
| Known as | EC-MPS | “The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro...” NCT00434590 ↗40“In a prospective clinical trial, the immunosuppressive therapy of renal graft recipients was converted from MMF to enteric-coated mycophenolate sodium (EC-MPS) to identify a...” PMID 21693250 ↗ Jun 2011 “Enteric-Coated Mycophenolate Sodium (EC-MPS) Administration in Maintenance Renal Transplant Patients Receiving Cyclosporine Microemulsion (CsA-ME) and Steroids, for the...” NCT00239057 ↗ “To compare the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) versus azathioprine (AZA) in patients with active systemic lupus erythematosus (SLE) disease.” PMID 28450313 ↗ Apr 2017 “Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME” NCT00239031 ↗ “The benefit of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in terms of gastrointestinal symptom burden” PMID 18091520 ↗ Dec 2007 “treatment with enteric-coated mycophenolate sodium (EC-MPS) improves gastrointestinal (GI) tolerability compared with mycophenolate mofetil (MMF).” PMID 21760569 ↗ Aug 2011 “Myfortic® is an advanced, enteric coated formulation of mycophenolate sodium (EC-MPS) that delays the release of the active ingredient, MPA.” NCT00652834 ↗ “The study group received reduced-dose tacrolimus, 1080-1440 mg/day of enteric-coated mycophenolate sodium (EC-MPS), and corticosteroids.” PMID 29891834 ↗ Jun 2018 “Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.” NCT00351377 ↗ “Enteric-coated mycophenolate sodium (ECMPS) has been developed as an alternative agent” PMID 18261583 ↗ Jan 2008 |
| Known as | Enteric-Coated Mycophenolate Sodium | “Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME” NCT00239031 ↗6“Enteric-Coated Mycophenolate Sodium (EC-MPS)” NCT00154206 ↗ “Enteric-coated Mycophenolate sodium (EC-MPS)” NCT00284921 ↗ “Enteric-Coated Mycophenolate Sodium (EC-MPS)” NCT00239070 ↗ “Enteric Coated Mycophenolate Sodium (EC-MPS)” NCT00965094 ↗ “Enteric-Coated Mycophenolate Sodium (EC-MPS)” NCT00529269 ↗ “Enteric-Coated Mycophenolate Sodium (EC-MPS)” NCT00537862 ↗ |
| Known as | Enteric-coated mycophenolate sodium: EC-MPS, Myfortic | “Enteric-coated mycophenolate sodium: EC-MPS, Myfortic” NCT00890253 ↗ |
| Known as | ERL080 | “This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in de novo heart recipients.” NCT00574743 ↗ |
| Known as | MMF | “Mycophenolatemofetil(MMF) is widely used in solid organ transplantation and it reduces the rate of acute rejection following renal transplantation.” NCT04424602 ↗1“mycophenolate (MMF) will begin from D+5.” NCT06646497 ↗ |
| Known as | MPA | “Mycophenolate sodium (MPA)” NCT00371826 ↗ |
| Known as | MPS | “Mycophenolate sodium (MPS) with enteric coating was developed with intention of reducing such gastrointestinal adverse events associated with MPA.” PMID 26398638 ↗ Jul 20151“Mycophenolate sodium (MPS)” NCT01056822 ↗ |
| Known as | Mycophenolate | “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗29“Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of...” NCT04177095 ↗ “standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone” NCT06584773 ↗ “Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate” NCT03917797 ↗ “Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28.” NCT03434704 ↗ “tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)” NCT04936282 ↗ “conversion of azathioprine or mycophenolate to sirolimus” NCT02671318 ↗ “followed by mycophenolate for maintenance therapy” NCT01639339 ↗ “mycophenolate (MMF) will begin from D+5.” NCT06646497 ↗ |
| Known as | Mycophenolatemofetil | “Mycophenolatemofetil(MMF) is widely used in solid organ transplantation and it reduces the rate of acute rejection following renal transplantation.” NCT04424602 ↗ |
| Known as | Mycopherol sodium enteric-coated tablets | “Mycopherol sodium enteric-coated tablets (EC-MPS)” NCT05872568 ↗ |
| Known as | Myfortic | “The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro...” NCT00434590 ↗8“Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention...” NCT00574197 ↗ “Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.” NCT00676221 ↗ “Myfortic® (mycophenolate sodium) may be used as a replacement for MMF.” NCT01790594 ↗ “Myfortic (Enteric Coated Mycophenolate Sodium) Conversion” NCT01807767 ↗ “Enteric-coated mycophenolate sodium (Myfortic)” NCT00419926 ↗ “Enteric-Coated Mycophenolate Sodium(Myfortic®)” NCT01817322 ↗ “Myfortic® (mycophenolic acid delayed release)” NCT00533624 ↗ “Original EC-MPS（myfortic）” NCT05872568 ↗ |
| Known as | Ruiyirong | “Imitation EC-MPS(Ruiyirong)” NCT05872568 ↗ |
| Known as | Sodium Mycophenolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02084446 ↗ |
| Route | Oral | “Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium” NCT00239005 ↗ |